The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 2.16%.However, over the last six months, we can see a stronger performance of -89.92%. Over the last 30 days, the price of CNSP has fallen by 18.73%. And in the last five days, it has surged by 7.05%.
Cns Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $61.00 on 01/08/24 and the lowest value was $0.10 on 08/16/24.
52-week price history of CNSP Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cns Pharmaceuticals Inc’s current trading price is -99.80% away from its 52-week high, while its distance from the 52-week low is 28.80%. The stock’s price range during this period has varied between$0.10 and $61.00. The Cns Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 37.86 million for the day, a figure considerably higher than their average daily volume of 16.7 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cns Pharmaceuticals Inc (CNSP) has experienced a quarterly rise of 2.41% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 7.44M and boasts a workforce of 5 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.1297, with a change in price of -0.0385. Similarly, Cns Pharmaceuticals Inc recorded 11,969,836 in trading volume during the last 100 days, posting a change of -23.84%.
CNSP’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CNSP stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
CNSP Stock Stochastic Average
Cns Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 9.96%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 72.61%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 72.62% and 72.48%, respectively.
